Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt

Rapid Dose Therapeutics Corp. (CSE: DOSE) announced today that pursuant to the terms of its amended and restated secured convertible notes dated December 1, 2025 (the "Notes"), the Company issued common shares ("Common Shares") in satisfaction of the accrued interest payable on June 30, 2026. The Notes were issued as a result of an extension to the promissory notes that were originally issued by the Company pursuant to its private placement financing (the "Financing") that closed in 2023. The Financing was an offering of units (the "Units") at a price of $1.00 per Unit. Each Unit consisted of $1.00 principal amount of Notes and five common share purchase warrants of the Company (the "Warrants"). The Company closed all four tranches of the Financing in 2023, issuing an aggregate of $3,134,445 principal amount of Notes and 15,672,225 Warrants. As previously disclosed, the Company agreed with noteholders holding an aggregate of $3,084,445 of promissory notes to extend the maturity date for one year on their respective notes to November 30, 2026, and extend the expiry date for one year on their accompanying 15,422,225 Warrants to November 30, 2026. The Notes bear interest at 18% per annum, calculated and compounded monthly, and added to principal and payable quarterly in arrears in Common Shares at a price per share equal to the closing market price of the Common Shares on the Canadian Securities Exchange (the "CSE") on the last trading day of each calendar quarter. The Company is permitted to prepay the Notes on 10 days' advance notice without notice or bonus. Therefore, in accordance with the terms of the Notes, the Company issued a total of 1,338,091 Common Shares to the holders of the Notes at a deemed issue price of $0.105 per Common Share, being the closing market price of the Common Shares on the CSE on June 30, 2026 (the last trading day of the quarter), in...